HBV Status and Outcomes of TACE-Lenvatinib-PD-1 Therapy in Unresectable HCC

A single-center retrospective cohort study of 190 patients with initially unresectable hepatocellular carcinoma (HCC) treated with triple therapy between February 2022 and February 2025. The dataset, authored by Yuhao Su and shared on figshare, compares clinical outcomes between hepatitis B virus (HBV)-positive and HBV-negative patient groups. It includes data on surgical conversion rates, overall survival, progression-free survival, and tumor response.

Use Cases

• Assess the association between HBV infection status and surgical conversion rates based on patient stratification.
• Compare overall survival and progression-free survival outcomes between patient groups using propensity score-matched analysis.
• Evaluate tumor response rates (ORR and DCR) according to the mRECIST criteria for different patient cohorts.
• Identify independent prognostic factors for survival outcomes based on multivariate Cox regression analysis.

Strengths

• Includes data from 190 consecutive patients, providing a defined cohort size.
• Uses propensity score matching (1:1, caliper 0.02) to balance baseline characteristics, strengthening comparative analysis.
• Reports specific clinical endpoints including surgical conversion rates (e.g., 25.6% vs. 12.3%), median OS, and median PFS with statistical significance values.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data tables is unknown, which may limit suitability assessment.
• Data is from a single-center retrospective study, which may limit generalizability.

Provenance

Source

figshare, author Yuhao Su.

Collection Method

Retrospective single-center cohort study.

Time Range

Patient treatment period from February 2022 to February 2025.

Freshness

Last updated 2026-04-23 05:35:31; freshness should be verified.